Dr Pegah Varamini's Breast Cancer Research
People often don’t believe me when I tell them about my research into turmeric as a treatment for breast cancer.
Turmeric? Surely something so simple, sitting in our kitchen cupboards can’t be the answer for one of the most challenging types of breast cancer?
But it can be. Right now, triple-negative breast cancer patients only have chemotherapy as a treatment option -, which targets normal cells as well as cancer cells.
I have developed an approach that allows curcumin, the active ingredient in turmeric, to specifically attack cancerous cells.
With your help, I would be able to work towards starting clinical trials and see how this exciting approach could work for different breast cancers.
Most importantly, I could help give breast cancer patients more than one option.
Dr Pegah Varamini
Donate today to further Dr Pegah Varamini's ground-breaking research and improve the treatment and survival rate of breast cancer patients.
Dr Pegah Varamini is a researcher, lecturer and group leader in the cancer theme at the Sydney School of Pharmacy. Her research focus is on triple-negative breast cancer (TNBC) which affects around 15 per cent of breast cancer patients.
TNBC is one of the most challenging types of breast cancer for which there are currently no targeted therapies. General chemotherapy is the only available option for these patients.
In her research Dr Varamini uses curcumin, the active ingredient of turmeric, which has been shown to have potential use in the treatment of conditions such as cancer and inflammation.
It cannot be used as a medicine in its raw form, “that means, drinking a turmeric latte at a coffee shop or taking a capsule of turmeric will not treat cancer,” said Dr Varamini.
Dr Varamini used a ‘trojan horse’ approach and a technology that involved nano-vesicles decorated with antennas that can discriminate normal cells from cancer cells. The vesicles containing curcumin only target cancer cells whereas, general chemotherapy affects normal cells as well.
Dr Varamini's next step is to examine the therapeutic agent in different breast cancer models. If successful, the study will move on to include human clinical trials.
All donations over $2 are tax deductible. If you are not in a position to give, please share this page.
Dr Pegah Varamini is an early career researcher, lecturer and group leader in Cancer Theme within the School of Pharmacy. She is the leader of Breast Cancer Targeting-Drug Delivery Group. Dr Varamini was awarded the prestigious National Breast Cancer Foundation (NBCF) fellowship and grant in Jan 2016.
For more information on Dr Pegah Varamini.